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Letters to the Editor
Immunological detection of occult blood in faeces in
colorectal cancer
Sir - The above paper by Turunen et al. (1984)
provides interesting data about the relative
sensitivities of FECA-EIA, an immunological test
for human haemoglobin (Hb), and four guaiac tests
for the detection of faecal occult blood. The
authors also present data on blood loss in 19
patients with colorectal cancer. The observation
that blood loss from cancers in the R. hemicolon is
greater than that from cancers in the L. hemicolon
and rectum confirms our findings (Macrae & St.
John, 1982). However the authors draw the
additional conclusion that blood loss is related to
tumour stage, incorrectly stating that this is similar
to our findings.
The issue about a relationship between blood loss
and tumour stage is important as it has
implications for the likely situation in early cancers
that may be diagnosed in screening programmes.
We have reviewed our data based on 380 twenty-
four hour faecal samples obtained from 46 patients
with colorectal cancer. For the purposes of
comparison, the results have been grouped as in the
article by Turunen et al. (Table). Separate analyses
of variance were performed on log-transformed
measurements of mean daily blood loss and mean
faecal Hb concentration to assess their relationship
with tumour site and stage. Blood loss (P<0.001)
and Hb concentration (P<0.01) varied significantly
with site of tumour. Stage had no effect after fitting
site. Furthermore, there was no interaction between
Table Relationship between geometric mean levels of
blood loss and tumour site and stage in 46 patients with
colorectal cancer.
No. of Blood loss Blood loss
Patients mlday-l mgHbg-l
R. Hemicolon
DukesA& B 8 12.5 19.5
Dukes C & D 2 3.0 4.5
L. Hemicolon
Dukes A & B 10 1.9 3.1
Dukes C & D 8 1.9 2.9
Rectum
Dukes A & B 10 2.0 2.8
DukesC&D 8 1.5 2.3
site and stage. In claiming a correlation between
blood loss and tumour stage, it appears that the
authors have failed to allow for the effect of site of
tumour on the results.
Yours etc.
D. James B. St. John,
F.A. Macrae.
Department of Gastroenterology,
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Dr Turunen & colleagues reply:
Sir - It is possible that the significant correlation
between faecal blood loss and tumour stage in
colorectal cancer observed by us might reflect an
Table Relationship between geometric mean levels of
blood loss and tumour site and stage in 19 patients with
colorectal cancer.
No. of Blood loss Blood loss
Patients mlday-1 mgHbg-1
R. Hemicolon
Dukes A & B 2 9.6 7.2
Dukes C & D 4 25.8 23.6
L. Hemicolon
Dukes A & B 6 2.7 4.3
Dukes C & D 2 4.7 6.9
Rectum
Dukes A & B 3 1.7 1.6
DukesC&D 2 7.1 4.8
effect of tumour site on the results, as we have also
observed that patients with cancer in the right
hemicolon excrete more blood than those with
cancer in the left hemicolon and rectum. However,
our results from 19 patients, grouped as in the
Table presented by St. John and Macrae, do not
support such a conclusion. Admittedly, the number
of observations per group is small and not suitable
for statistical analysis. We therefore welcome the
report of St. John and Macrae on 46 patients. Even
larger materials will be needed for ultimate
conclusions on this controversial and important
issue. We apologize to Drs. St. John and Macrae
for incorrect citation of their earlier report and for
any inconvenience this might have caused them.
Yours etc.
M.J. Turunen, K. Liewendahl, P. Partanen,
H. Adlercreutz
Second Dept. of Surgery,
Dept. of Clinical Chemistry,
Helsinki University Central Hospital and
Labsystems Research Lab., Labsystems Corp.,
Helsinki, Finland.